Nurix Therapeutics Inc (NAS:NRIX)
$ 15.4 -0.5 (-3.14%) Market Cap: 940.44 Mil Enterprise Value: 756.14 Mil PE Ratio: 0 PB Ratio: 4.63 GF Score: 67/100

Nurix Therapeutics Inc at Guggenheim Healthcare Talks: Targeted Protein Degradation Day (Virtual) Transcript

Mar 16, 2022 / 03:00PM GMT
Release Date Price: $13.92 (+3.57%)
Michael Schmidt
Guggenheim Securities, LLC - Senior Biotech Analyst

All right. Hello and welcome. Thanks for joining us. My name is Michael Schmidt, senior biotech analyst with Guggenheim Securities. And I'm very excited to welcome the Nurix Therapeutics team presenting today. With us today, we have our Arthur Sands, CEO; Hans van Houte, CFO; and Robert Brown, Head of Clinical. Welcome and thanks for joining us.

Arthur Sands
Nurix Therapeutics, Inc. - President, CEO and Board Director

Thank you. Thanks for having us, Michael.

Hans van Houte
Nurix Therapeutics, Inc. - CFO

Thanks, Michael.

Michael Schmidt
Guggenheim Securities, LLC - Senior Biotech Analyst

All right. I think we'll start with a brief overview, and then we'll jump into Q&A. Any investor questions, please send me an e-mail. I'll try to work those in.

Arthur Sands
Nurix Therapeutics, Inc. - President, CEO and Board Director

Thank you. So Nurix Therapeutics

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot